| Abstrakt: |
A recent report from the Medical University of Bialystok in Poland explores the molecular mechanisms of trastuzumab resistance in HER2-positive breast cancer. Trastuzumab is a monoclonal antibody used to target HER2, a protein associated with this type of breast cancer. The study used two breast cancer cell lines, SKBR3 and BT474, and optimized trastuzumab treatment doses for each cell line. Gene and microRNA expression analysis revealed several genes and miRNAs responsible for trastuzumab resistance. The findings provide new insights into the development of resistance to trastuzumab in HER2-positive breast cancer. [Extracted from the article] |
